Long-term incidence and prognostic factors of the progression of new coronary lesions in Japanese coronary artery disease patients after percutaneous coronary intervention

详细信息    查看全文

• 作者：Hidehiro Kaneko (1)
  Junji Yajima (1)
  Yuji Oikawa (1)
  Shingo Tanaka (1)
  Daisuke Fukamachi (1)
  Shinya Suzuki (1)
  Koichi Sagara (1)
  Takayuki Otsuka (1)
  Shunsuke Matsuno (1)
  Hiroto Kano (1)
  Tokuhisa Uejima (1)
  Akira Koike (1)
  Kazuyuki Nagashima (1)
  Hajime Kirigaya (1)
  Hitoshi Sawada (1)
  Tadanori Aizawa (1)
  Takeshi Yamashita (1)
  
• 关键词：New culprit coronary artery lesion ; Percutaneous coronary intervention ; High ; density lipoprotein cholesterol ; Insulin ; Japanese
• 刊名：Heart and Vessels
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：29
• 期：4
• 页码：437-442
• 全文大小：178 KB
• 参考文献：1. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R (2010) In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 56:1897-907 CrossRef
  2. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A (2006) Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113:2293-300 CrossRef
  3. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A (1998) Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32:1866-873 CrossRef
  4. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428-436 CrossRef
  5. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, Yamashita T (2012) Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 76:607-11 CrossRef
  6. Suzuki S, Yamashita T, Ohtsuka T, Sagara K, Uejima T, Oikawa Y, Yajima J, Koike A, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T (2008) Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken Database 2004. Circ J 72:914-20 CrossRef
  7. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-92 CrossRef
  8. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M (2006) Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 332:1426 CrossRef
  9. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB (1999) Annual deaths attributable to obesity in the United States. JAMA 282:1530-538 CrossRef
  10. St Jeor ST, Brownell KD, Atkinson RL, Bouchard C, Dwyer J, Foreyt JP, Heber D, Kris-Etherton P, Stern JS, Willett W (1993) Obesity. Workshop III. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health. Circulation 88:1391-396 CrossRef
  11. Park MW, Seung KB, Kim PJ, Park HJ, Yoon SG, Baek JY, Koh YS, Jung HO, Chang K, Kim HY, Baek SH (2009) Long-term percutaneous coronary intervention rates and associated independent predictors for progression of nonintervened nonculprit coronary lesions. Am J Cardiol 104:648-52 CrossRef
  12. Glaser R, Selzer F, Faxon DP, Laskey WK, Cohen HA, Slater J, Detre KM, Wilensky RL (2005) Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 111:143-49 CrossRef
  13. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K (2012) Very Late Stent Thrombosis And Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation: Five-Year Outcome Of The j-Cypher Registry. Circulation 125:584-91 CrossRef
  14. Gordon DJ, Rifkind BM (1989) High-density lipoprotein—the clinical implications of recent studies. N Engl J Med 321:1311-316 CrossRef
  15. Castelli WP (1983) Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 106:1191-200 CrossRef
  16. Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM (1976) Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 88:941-57
  17. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L (2012) Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125:1905-919 CrossRef
  18. Oram JF, Johnson CJ, Brown TA (1987) Interaction of high-density lipoprotein with its receptor on cultured fibroblasts and macrophages. Evidence for reversible binding at the cell surface without internalization. J Biol Chem 262:2405-410
  19. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE (1991) Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 68:1425-430 CrossRef
  20. Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881-888 CrossRef
  21. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM (2004) Antiinflammatory properties of HDL. Circ Res 95:764-72 CrossRef
  22. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML (1985) Activation of fibrinolysis by apolipoproteins of high-density lipoproteins in man. Thromb Res 39:1- CrossRef
  23. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103:219-27 CrossRef
  24. Epand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM (1994) HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 14:1775-783 CrossRef
  25. Aoyama T, Yui Y, Morishita H, Kawai C (1990) Prostaglandin I2 half-life regulated by high-density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 81:1784-791 CrossRef
  26. National Cholesterol Education Program Coordinating Committee (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-421
  27. Norhammar A, Lagerqvist B, Saleh N (2010) Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry. Euro Intervention 5:891-97
  28. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177-84 CrossRef
  29. McGuire DK, Newby LK, Bhapkar MV, Moliterno DJ, Hochman JS, Klein WW, Weaver WD, Pfisterer M, Corbalan R, Dellborg M, Granger CB, Van De Werf F, Topol EJ, Califf RM (2004) Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 147:246-52 CrossRef
  30. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, Bonadonna RC (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576-82 CrossRef
  31. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Bass TA, Macaya C, Fernandez-Ortiz A (2006) Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 48:298-04 CrossRef
  
• 作者单位：Hidehiro Kaneko (1)
  Junji Yajima (1)
  Yuji Oikawa (1)
  Shingo Tanaka (1)
  Daisuke Fukamachi (1)
  Shinya Suzuki (1)
  Koichi Sagara (1)
  Takayuki Otsuka (1)
  Shunsuke Matsuno (1)
  Hiroto Kano (1)
  Tokuhisa Uejima (1)
  Akira Koike (1)
  Kazuyuki Nagashima (1)
  Hajime Kirigaya (1)
  Hitoshi Sawada (1)
  Tadanori Aizawa (1)
  Takeshi Yamashita (1)
  
  1. The Department of Cardiovascular Medicine, The Cardiovascular Institute, 3-2-19 Nishiazabu, Minato-ku, Tokyo, 106-0031, Japan
  
• ISSN：1615-2573

文摘

Revascularization of an initially non-target site due to its progression as a new culprit lesion has emerged as a new therapeutic target of coronary artery disease (CAD) in the era of drug-eluting stents. Using the Shinken database, a single-hospital-based cohort, we aimed to clarify the incidence and prognostic factors for progression of previously non-significant coronary portions after prior percutaneous coronary intervention (PCI) in Japanese CAD patients. We selected from the Shinken database a single-hospital-based cohort of Japanese patients (n?=?15227) who visited the Cardiovascular Institute between 2004 and 2010 to undergo PCI. This study included 1,214 patients (median follow-up period, 1,032?±?704?days). Additional clinically driven PCI to treat previously non-significant lesions was performed in 152 patients. The cumulative rate of new-lesion PCI was 9.5?% at 1?year, 14.4?% at 3?years, and 17.6?% at 5?years. There was no difference in background clinical characteristics between patients with and without additional PCI. Prevalence of multi-vessel disease (MVD) (82 vs. 57?%, p?p?=?0.028) were significantly higher and high-density lipoprotein cholesterol (HDL) level (51?±?15 vs. 47?±?12?mg/dl, p?p?=?0.035) were more common in patients with additional PCI. Multivariate analysis showed that MVD, lower HDL, and insulin use were independent determinants of progression of new culprit coronary lesions. In conclusion, progression of new coronary lesions was common and new-lesion PCI continued to occur beyond 1?year after PCI without attenuation of their annual incidences up to 5?years. Greater coronary artery disease burden, low HDL, and insulin-dependent DM were independent predictors of progression of new culprit coronary lesions.